AMANDA HARMON: Open Payments
NPI 1093407041 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$588 in 32 payments from 12 companies in 2025. Trend: 2023 $302 · 2024 $525 · 2025 $588
Food & beverage: $588
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 4 | $113 |
| MILLICENT US INC | 4 | $80 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $77 |
| MAYNE PHARMA COMMERCIAL LLC | 7 | $63 |
| Biogen, Inc. | 2 | $57 |
| Exeltis, USA Inc. | 3 | $49 |
| ABBVIE INC. | 2 | $36 |
| Kerecis Limited | 1 | $28 |
| CooperSurgical, Inc. | 1 | $27 |
| Octapharma USA, Inc. | 1 | $22 |
Products named: Veozah, ZURZUVAE, SLYND, Mirena, FEMLYV, INTRAROSA, LILETTA, Kerecis SurgiClose.
Industry payments across IN — which companies pay providers there.
